Incyte
FDA sets April date for verdict on Incyte’s vitiligo drug
Phil Taylor
dermatology, fda, Incyte, Opzelura, regulatory, vitiligo
0 Comment
Incyte leads JAK push into eczema as FDA clears Opzelura cream
Phil Taylor
dermatology, fda, Immunology and inflammation, Incyte, JAK inhibitor, Opzelura, regulatory approval
0 Comment
Incyte, MorphoSys’ CAR-T rival tafasitamab approved in EU
Phil Taylor
CAR-T therapies, EU, Incyte, MorphoSys, non-Hodgkin lymphoma, regulatory approval, tafasitamab
0 Comment
Lilly has a bad hair day as Pfizer rival hits the mark in alopecia
Phil Taylor
alopecia, autoimmune disease, Concert Pharma, Eli Lilly, Incyte, JAK inhibitor, Pfizer
0 Comment
NICE changes its mind on rare bile duct cancer drug from Incyte
Phil Taylor
cholangiocarcinoma, HEOR, Incyte, NICE, Oncology, Pemazyre, pemigatinib, targeted oncology
0 Comment
Incyte preps second filing for ruxolitinib cream after vitiligo trial win
Richard Staines
dermatology, Incyte, ruxolitinib, vitiligo
0 Comment
Incyte makes bid to join the checkpoint inhibitor club
Phil Taylor
fda, immuno-oncology, Incyte, Oncology, Priority Review, retifanlimab
0 Comment